Another study finds dolutegravir-based ART during pregnancy is safe, effective

According to the researchers, 96.7% of participants who received dolutegravir were virally suppressed at delivery, compared with 84% for atazanavir-ritonavir, 90.1% for darunavir-ritonavir, 89.2% for raltegravir, and 89.8% for elvitegravir-cobicistat. [...]observational perinatal studies will continue to be important to evaluate new antiretroviral drugs in pregnancy after they are introduced into clinical practice among adults living with HIV. - by Melinda Stevens * PERSPECTIVE Dolutegravir-based ART is now the mainstay of first-line therapy for HIV infection worldwide. The study provides further evidence of the safety of dolutegravir when used by the mother to the infant, adding to recent data from other cohorts. Because dolutegravir is now first-line therapy worldwide, these findings are reassuring to millions of women living with HIV and their providers. -